ETBX-011
- Generic Name
- ETBX-011
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- RP9RQ0SOM8
- Background
ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).
- Associated Conditions
- -
- Associated Therapies
- -
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
Phase 1
Terminated
- Conditions
- Interventions
- Biological: Aldoxorubicin HydrochlorideBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNKDrug: AvelumabDrug: CapecitabineDrug: CetuximabDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: Nab-paclitaxelDrug: OxaliplatinDrug: RegorafenibProcedure: SBRT
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03563157
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03329248
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath